{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:38Z","timestamp":1790776478139,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007337","name":"Massachusetts Eye and Ear","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ajo.2026.07.030","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:48:34Z","timestamp":1784533714000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS Registry Analysis"],"prefix":"10.1016","volume":"291","author":[{"given":"Yi Stephanie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Chaaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3946-7844","authenticated-orcid":false,"given":"Eric A.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-4494","authenticated-orcid":false,"given":"Ryan S.","family":"Meshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srujay","family":"Pandiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-360X","authenticated-orcid":false,"given":"Sandra","family":"Hoyek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-0496","authenticated-orcid":false,"given":"Tobias","family":"Elze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-3996","authenticated-orcid":false,"given":"Joan W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-6104","authenticated-orcid":false,"given":"Nimesh A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0001","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1469-0691.12118","article-title":"Endophthalmitis","volume":"19","author":"Durand","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"21","key":"10.1016\/j.ajo.2026.07.030_bib0002","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ajo.2026.07.030_bib0003","doi-asserted-by":"crossref","first-page":"xli","DOI":"10.1016\/j.ajo.2017.12.019","article-title":"Evolution of intravitreal therapy for retinal diseases\u2014from CMV to CNV: the LXXIV Edward Jackson Memorial Lecture","volume":"191","author":"Martin","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/157339911795843104","article-title":"Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery","volume":"7","author":"Montero","year":"2011","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.ajo.2026.07.030_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","article-title":"Drug approval for the treatment of geographic atrophy: how we got here and where we need to go","volume":"263","author":"Csaky","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1469-0691.12118","article-title":"Endophthalmitis","volume":"19","author":"Durand","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0007","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti\u2013vascular endothelial growth factor agents: causative organisms and possible prevention strategies","volume":"31","author":"McCannel","year":"2011","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.ajo.2026.07.030_bib0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ophtha.2023.12.033","article-title":"Risk of endophthalmitis based on cumulative number of anti-VEGF intravitreal injections","volume":"131","author":"Israilevich","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2013.08.037","article-title":"The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection","volume":"121","author":"Storey","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2026.07.030_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3928\/23258160-20210528-03","article-title":"Rates of suspected endophthalmitis following intravitreal injections in clinical practices in the United States","volume":"52","author":"Dhoot","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.030_bib0011","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/IAE.0000000000002351","article-title":"Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab","volume":"39","author":"Bavinger","year":"2019","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100112","article-title":"American Academy of Ophthalmology Intelligent Research in Sight (IRIS\u00ae) Registry and the IRIS Registry Analytic Center Consortium","volume":"2","author":"Lee","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100933","article-title":"Data duplication and errors in large medical Data sets: a case study in the IRIS\u00ae registry","volume":"6","author":"Goldberg","year":"2026","journal-title":"Ophthalmol Sci"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0014","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.oret.2024.09.002","article-title":"Intravitreal Antibiotics versus early vitrectomy plus intravitreal antibiotics for postinjection endophthalmitis: an IRIS\u00ae (Intelligent Research in Sight Registry) analysis","volume":"9","author":"Ross","year":"2025","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"10.1016\/j.ajo.2026.07.030_bib0015","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.ophtha.2015.07.005","article-title":"The association between intravitreal steroids and post-injection endophthalmitis rates","volume":"122","author":"VanderBeek","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.07.030_bib0016","first-page":"1","article-title":"Safety profile of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies","author":"Querques","year":"2025","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","article-title":"A collaborative retrospective study on the efficacy and safety of intravitreal Dexamethasone implant (Ozurdex) in patients with diabetic macular edema","volume":"127","author":"Rosenblatt","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0018","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaophthalmol.2016.5883","article-title":"Incidence and visual outcomes of culture-proven endophthalmitis following Dexamethasone Intravitreal implant","volume":"135","author":"Stem","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0019","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ajo.2007.04.011","article-title":"The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials","volume":"144","author":"Bhavsar","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.030_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4155\/tde-2019-0051","article-title":"Preliminary evaluation of YUTIQTM (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis","volume":"10","author":"Testi","year":"2019","journal-title":"Ther Deliv"},{"key":"10.1016\/j.ajo.2026.07.030_bib0021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000336330","article-title":"Corticosteroid intravitreal implants","volume":"51","author":"de Smet","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.030_bib0022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000434692","article-title":"Routes for drug delivery: sustained-release devices","volume":"55","author":"Yun","year":"2016","journal-title":"Dev Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2026.07.030_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100527","article-title":"Phase I DAVIO trial: EYP-1901 bioerodible, sustained-delivery vorolanib insert in patients with wet age-related macular degeneration","volume":"4","author":"Patel","year":"2024","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tjo.2015.03.004","article-title":"Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention","volume":"5","author":"Hornbeak","year":"2015","journal-title":"Taiwan J Ophthalmol"},{"issue":"17","key":"10.1016\/j.ajo.2026.07.030_bib0025","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 TRIAL","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (L)"},{"issue":"10411","key":"10.1016\/j.ajo.2026.07.030_bib0026","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.030_bib0027","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor Pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.07.030_bib0028","article-title":"Rates of endophthalmitis in prefilled versus non-prefilled syringes for intravitreal injections: a systematic review and meta-analysis","author":"Zhang","year":"2025","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"10.1016\/j.ajo.2026.07.030_bib0029","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/jcm14072491","article-title":"Comparison of endophthalmitis rates between prefilled syringes and standard vials in Aflibercept intravitreal injections: a retrospective study in Japan","volume":"14","author":"Morioka","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajo.2026.07.030_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/OPTH.S393519","article-title":"Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022","volume":"17","author":"Schmidt-Ott","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.030_bib0031","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/164_2016_22","article-title":"Corticosteroids and anti-complement therapy in retinal diseases","volume":"242","author":"Narayanan","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0032","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2016.10.036","article-title":"Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and Medicare advantage patients","volume":"124","author":"Parikh","year":"2017","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2026.07.030_bib0033","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaophthalmol.2019.1971","article-title":"Analysis of anti\u2013vascular endothelial growth factor injection claims data in US Medicare part B beneficiaries from 2012 to 2015","volume":"137","author":"Berkowitz","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2026.07.030_bib0034","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti\u2013Vascular growth factor agents in a nationwide study in France","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.07.030_bib0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3928\/23258160-20140306-08","article-title":"Meta-analysis of infectious Endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"45","author":"Fileta","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0036","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bjophthalmol-2012-302435","article-title":"Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates","volume":"97","author":"Englander","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0037","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2015.04.013","article-title":"Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome","volume":"160","author":"Dossarps","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40942-015-0010-y","article-title":"Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review","volume":"1","author":"Merani","year":"2015","journal-title":"Int J Retin Vitr"},{"issue":"6","key":"10.1016\/j.ajo.2026.07.030_bib0039","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ophtha.2022.01.009","article-title":"The pandemic is not associated with endophthalmitis decrease after anti-vascular endothelial growth factor injections","volume":"129","author":"Lum","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2026.07.030_bib0040","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11845-022-02929-8","article-title":"Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy","volume":"192","author":"Kilmartin","year":"2023","journal-title":"Ir J Med Sci"},{"issue":"10","key":"10.1016\/j.ajo.2026.07.030_bib0041","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/IAE.0000000000004179","article-title":"Intravitreal 0.18-mg fluocinolone acetonide implant for pediatric uveitis","volume":"44","author":"Wangyu","year":"2024","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.07.030_bib0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/ICU.0000000000000650","article-title":"Recent developments in pediatric retina","volume":"31","author":"Cai","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0043","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta-analysis","volume":"69","author":"Ortiz-Seller","year":"2024","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.07.030_bib0044","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber Effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:56:05Z","timestamp":1790772965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":44,"alternative-id":["S0002939426004071"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.030","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS Registry Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}